Brain Functional Connectivity in Alcohol Use Disorder
Completed
Conditions studied: Alcohol Use Disorder
In brief
Due to the relapsing nature of alcoholism, excessive alcohol consumption represents a significant cost to US society ($249 billion in 20101). About 64% of those entering treatment will relapse within one year. New interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. Using resting functional magnetic resonance imaging (fMRI) we have identified brain biomarkers that support long-term abstinence and brain biomarkers that predict relapse. Our data point to specific brain biomarkers that index higher relapse vulnerability at 11 weeks of abstinence. Many individuals, however, have already relapsed by this time. It is unknown whether these biomarkers can be identified earlier during the recovery period. We need to investigate whether this biomarker of relapse vulnerability can be identified during earlier stages of abstinence. Earlier identification of this biomarker will give valuable information for timely targeted interventions (e.g. closer monitoring, longer stay in treatment program, neuromodulation), increasing the chances of maintaining abstinence. The overall objective of this study is to identify biomarkers of relapse during early abstinence (2-3 weeks of abstinence). A secondary objective is to evaluate whether non-imaging measures such as craving6 and executive function7 add value to prediction models. Findings from this proposal will provide insight into the neurobiology of relapse vulnerability that will inform new treatment strategies needed to improve treatment outcome.
Key facts
- Study ID
- NCT02877849
- Run by
- University of Minnesota
- People needed
- 82
- Starts
- 2017-02-09
- Expected to finish
- 2019-10-31
- Last updated by the study team
- 2019-11-06
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age 18-60
- Ability to provide written consent and comply with study procedures
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for Alcohol Use Disorder
- May have current comorbid drug use, but primary substance use disorder diagnosis needs to be based on alcohol use
- Must be enrolled in Lodging Plus (Fairview Riverside) treatment program
- Must have the intention to remain in program until the end of the study
You may not qualify if…
- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness>30 min, HIV)
- Any MRI scanning contraindications (i.e., metal implants, pacemakers, etc.)
- DSM-V criteria for psychiatric disorder, may have a lifetime but not current diagnosis of depression
- Primary current substance use disorder diagnosis on a substance other than alcohol except for caffeine or nicotine
- Clinical evidence for Wernicke-Korsakoff syndrome
- Healthy controls
- INCLUSION CRITERIA:
- Age 18-60
- Ability to provide written consent and comply with study procedures
- EXCLUSION CRITERIA:
- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness>30 min, HIV)
- Any MRI scanning contraindications (i.e., metal implants, pacemakers, etc.)
- DSM-V criteria for psychiatric disorder, may have a lifetime but not current diagnosis of depression
- Primary current substance use disorder diagnosis on any substance such as alcohol, stimulant, opioids, etc. except for caffeine or nicotine
Where it is running
- University of Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.